With a market capitalization (market cap) of $1.46B — a measure of how much the company is worth — Maze Therapeutics, Inc. ranks #2,263 among the 2,510 companies tracked, and 306th in Healthcare as of October 3, 2026. Shares trade at $26.43, down 0.83% on the day.
of 2,510 tracked
Market-cap change uses historical capitalization records. Share-price returns are a different series — they can diverge when the share count changes. Those returns are not a CAGR until you pick a start value, an ending value, and years. CAGR calculator. Market cap vs. stock price.
Year-end values and the chart both come from historical market-cap records, not from applying today's share count to past prices. Latest historical observation October 2, 2026. Ranking headline cap is the snapshot figure as of October 3, 2026.
| Year | As of | Market cap | Annual change | Year-end close |
|---|---|---|---|---|
| 2026 | Oct 2, 2026 | $1.56B | -30.17% | $26.43 |
| 2025 | Dec 31, 2025 | $2.23B | — | $41.43 |
Last observation of each calendar year from historical market-cap records. The current year is through the latest date, not a completed year-end. Share-price close is the matching session for context — we do not rebuild cap from today's share count.
Ranking figure $1.46B as of October 3, 2026.
Maze Therapeutics, Inc.'s ranking market cap is the provider-reported capitalization on the same snapshot as the rest of this site, with a share price of $26.43 as of October 2, 2026. Charts and the year-end table use a separate historical market-cap series, last observed at $1.56B on October 2, 2026. See how the ranking works.
The ranking snapshot ($1.46B as of October 3, 2026) is FMP company-screener market cap. The historical observation ($1.56B on October 2, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This page does not replace one series with the other.
Live shares outstanding are not on the quote used for price, so this page does not invent a current share count. Shares outstanding vs. float.
The latest annual report (FY 2025) used a weighted-average 42,976,024 shares. That figure is an average for the year, not the live count in the market-cap formula.
Multiplying the latest price by those FY 2025 weighted-average shares would give about $1.14B. The ranking uses the provider's reported market cap instead, which reflects a current share count rather than that annual average.
Book equity: assets minus liabilities on the latest annual report.
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
FY 2025
Undefined when revenue is zero
Undefined when revenue is zero
Undefined when revenue is zero
FY 2025
FY 2025
Undefined when revenue is zero
FY 2025
Undefined when revenue is zero
FY 2025
FY 2025
FY 2025
FY 2025
Not in this snapshot
FY 2025 net worth
Largest U.S.-listed names in the same FMP sector — not a hand-picked competitor set.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #14 | Eli Lilly and Company LLY | $1.08T | -0.61% |
| #21 | Johnson & Johnson JNJ | $617.01B | -1.02% |
| #24 |
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of kidney and metabolic diseases in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidney disease; and MZE782, an oral small molecule inhibitor that is in phase II ready clinical trial for the treatment of phenylketonuria and chronic kidney disease.
Summary from the company profile (Financial Modeling Prep). Principal financial figures above are for FY 2025.
Visit websiteAs of October 3, 2026, Maze Therapeutics, Inc. (MAZE) is worth $1.46B — that is its market capitalization, the total value of its outstanding shares on MarketCapLens.
A company’s net worth is its shareholders’ equity: assets minus liabilities on the balance sheet. That is book equity, not market cap. For FY 2025, Maze Therapeutics, Inc.’s book equity is about $354.97M. Market cap is the market value of the outstanding shares. As of October 3, 2026, its market cap is $1.46B. Book equity is an accounting remainder; market cap is a trading value. Neither is a person’s net worth.
Maze Therapeutics, Inc. ranks #2,263 among the 2,510 companies tracked on MarketCapLens. In Healthcare it ranks #306 of 350.
Fundamentals are annual. Figures labeled with their fiscal year. Live ratios use the current price against those annual earnings.
Too little price history
Over the past year, market cap and share price moved by different amounts. Share count can change independently of price. What changes market cap.
Not in this snapshot
FY 2025
| $464.35B |
| +1.11% |
| #36 | Merck & Co., Inc. MRK | $356.4B | +0.34% |
| #38 | UnitedHealth Group Incorporated UNH | $337.74B | +1.83% |
| #52 | Novartis AG NVS | $268B | -0.04% |
Companies immediately above and below in the overall ranking. They may be in a different sector.
| Rank | Company | Market cap | 1D |
|---|---|---|---|
| #2260 | Permian Basin Royalty Trust PBT | $1.47B | +0.83% |
| #2261 | J&J Snack Foods Corp. JJSF | $1.47B | +0.86% |
| #2262 | Innovative Industrial Properties, Inc. IIPR | $1.46B | -0.94% |
| #2264 | Capital Southwest Corporation CSWC | $1.46B | +0.94% |
| #2265 | Certara, Inc. CERT | $1.46B | +0.21% |
| #2266 | American Superconductor Corporation AMSC | $1.45B | +1.73% |
Maze Therapeutics, Inc.’s ranking market cap of $1.46B comes from the same snapshot as the rest of this site, as of October 3, 2026. It is not share price multiplied by the FY 2025 weighted-average share count of 42,976,024. The ranking snapshot ($1.46B as of October 3, 2026) is FMP company-screener market cap. The historical observation ($1.56B on October 2, 2026) is FMP historical-market-capitalization for the same ticker. The live quote market cap agrees with the ranking snapshot. This page does not replace one series with the other.
Over the past year, Maze Therapeutics, Inc.’s market cap is up 36.91%, using historical market-cap records rather than today’s share count applied to past prices.
Maze Therapeutics, Inc. (MAZE) shares trade at $26.43, down 0.83% on the day, as of October 3, 2026.
Live P/E is share price divided by annual earnings per share. Sales-based ratios such as price/sales and operating margin are also blank when revenue is zero — not a 0× multiple.